If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
== Formation == Initial funding for the formation of Onyx came from biotechnology firm Chiron Corporation (granted a 43% stake in the new company) and venture capital investors: Avalon Ventures, Institutional Venture Partners (IVP), J. H. Whitney & Company and Kleiner Perkins. McCormick had been working on cancer treatments at Chiron before he was selected as vice president of research at the newly formed company, leading the company's research program. The acting president of the firm at its inception was Samuel D. Colella, a partner at early investor, IVP.
== One Health approach == Antimicrobial resistance (AMR) is commonly described within a One Health framework, which emphasizes the interconnected relationships between human health, animal health, and the environment. Antimicrobial use in clinical medicine, veterinary practice, and agriculture has been associated with the selection and spread of resistant microorganisms across these sectors. Research indicates that resistant bacteria and antimicrobial resistance genes can move between humans, animals, and environmental reservoirs through multiple pathways, including food production systems, direct contact, and exposure to contaminated water or soil. These pathways contribute to the persistence and wider dissemination of antimicrobial resistance beyond individual settings. Environmental sources have been increasingly examined in relation to AMR. Wastewater systems, agricultural runoff, and pharmaceutical residues have been identified as potential reservoirs where resistant microorganisms and resistance genes may persist. Such reservoirs may facilitate ongoing transmission between environmental, animal, and human populations. Efforts to address AMR within a One Health framework typically involve coordinated strategies across sectors, including antimicrobial stewardship, infection prevention and control, and improvements in sanitation and hygiene.
== Research use == Since C. hemisphaerica passes through planula, polyp, and medusa stages during its life cycle, it is regarded as a good model for studying how one genome can produce variable phenotypes. This is especially useful when considering that two of the more common Cnidarian model organisms, Hydra and Nematostella, do not have the same "complete' life-cycle that alternates between a vegetative polyp and sexually reproducing, free-swimming medusa form. Clytia has characteristics that make it favorable for laboratory culture and experimental manipulation. All stages of Clytia's life cycle can be reproduced under laboratory conditions; polyp colonies, due to their essentially immortal nature, are easily maintained, and adult medusa can be fed with Artemia larvae. Adult male and female medusa spawn daily, and can be entrained with controlled light conditions to spawn at specific times. The oocytes, eggs, embryos, and planulae of Clytia are easily visualized under a microscope and, much like those of popular model organisms like sea urchins, the zygotes of C. hemisphaerica are relatively large (around 200 um in diameter) and can be microinjected to form transgenic planulae, polyp colonies, and medusa. Clytia is also unique in that its gonads can function autonomously; a gonad separated from an adult medusa will undergo oocyte development and ovulation under the same entrained light cues as would a gonad still attached to a medusa.
Microscope slides: Specimens can be mounted on microscope slides for short-term storage, however, there is a greater risk of rapid deterioration from contracting, darkening, or crystallizing specimens. Slides should be checked on an annual basis to check the condition of preserved specimens. Desiccants and freeze-drying: Silica gel or freeze-drying methods can be applied to specimens that require preservation of the shape of a delicate organ such as a flower. Disadvantages of this technique are that the specimen is especially fragile and lacks support. Acid-free tissue is often used for storage.
Sources: en.wikipedia.org
The mycobiont (fungal partner) of the lichen Lecidea tessellata has been shown to produce confluentic acid when cultured without its algal photobiont partner. Confluentic acid has also been reported from mycobiont cultures of Parmelina carporrhizans. Confluentic acid is produced by almost all species of the genus Immersaria, which is usually accompanied by 2'-O-methylmicrophyllinic acid. The absence of confluentic acid distinguishes Inoderma nipponicum, from others in genus Inoderma, which typically contain this chemical. The only character reliably distinguishing Porpidia contraponenda and the morphologically similar Porpidia cinereoatra is their secondary chemistry: the former contains 2'-O-methylmicrophyllinate and the latter has confluentic acid. A chemosyndrome is a set of biosynthetically related compounds produced by a lichen. The confluentic acid chemosyndrome was identified in several lichens in the family Lecideaceae; it contains confluentic acid as the major metabolite, and minor amounts of 2'-O-methylperlatolic acid, olivetonide monomethyl ether, and 2'-O-methylmicrophyllinic acid. Not just limited to lichen-forming fungi, confluentic acid has also been reported from the Brazilian plant Himatanthus sucuuba, highlighting the compound's broader biological distribution.
=== Cardiac conditions === Subtypes of troponin (cardiac I and T) are sensitive and specific indicators of heart muscle damage (myocardium). They are measured in the blood to differentiate between unstable angina and myocardial infarction (heart attack) in people with chest pain or acute coronary syndrome. A person who recently had a myocardial infarction has areas of damaged heart muscle and elevated cardiac troponin levels in the blood. This can also occur in people with coronary vasospasm, a type of myocardial infarction involving severe constriction of the cardiac blood vessels. After a myocardial infarction troponins may remain high for up to 2 weeks. Cardiac troponins are a marker of all heart muscle damage, not just myocardial infarction, which is the most severe form of heart disorder. However, diagnostic criteria for raised troponin indicating myocardial infarction is currently set by the WHO at a threshold of 2 μg/L or higher. Critical levels of other cardiac biomarkers are also relevant, such as creatine kinase. Severe tachycardia (for example due to supraventricular tachycardia) in an individual with normal coronary arteries can also lead to increased troponins for example, it is presumed due to increased oxygen demand and inadequate supply to the heart muscle. Coronary artery stent placement can also cause immediate post-procedure elevated serum cardiac troponin levels. This can be problematic in a clinical setting as troponin values and guidance protocols become subject to more thoughtful interpretation.
== In-house writers == Tania Carmenatti, Dana Meyers, Dennis "Den Den" Nelson, Dynasty members Nidra Beard & William Shelby, The Time member Ricky Darnell "Freeze" Smith, The Sylvers member Charmaine Sylvers, and Johnny Thomas Jr. were frequent writing collaborators on various SOLAR albums and/or for various SOLAR acts. Credits are courtesy of Tidal and Spotify. (A majority of Beard and Shelby's written contributions to their own group are omitted)
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.